Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.27 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: xl-418, afuresertib, uprosertib +12 | 0.90 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 79 Parkinson's papers of 10,202 | 0.42 |
| pathways Reactome | 43 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 1474
Sealed predictions
- AKT1 in dopamine neurons, braak-0.55 (p 0.128) → -0.45 (p 0.219)receipt 1481
Swarm cases
receipt 1481: AKT1 in dopamine neurons, braak
- power
- full sample -0.56 (p 0.016, n 18), 95% CI -0.81 to -0.12. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.56 (p 0.016, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.63 (p 0.0053, n 18). not the mix.
- skeptic
- leave-one-out range -0.67 to -0.50, sign flips 0; without severely affected donors -0.56 (p 0.016, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AKT1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts